Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery

NCT ID: NCT03739528

Last Updated: 2020-08-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

808 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-03

Study Completion Date

2018-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the non-inferiority of the study treatment (combined levofloxacin + dexamethasone eye drops) followed by dexamethasone eye drops alone vs. standard treatment in the prevention and treatment of postoperative ocular inflammation and prevention of infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In clinical practice, topical treatment following cataract surgery is frequently administered using a combination between an antibiotic and a corticosteroid to promote patient adherence to therapy and to obtain both prevention of infection and treatment of post-surgical inflammation.

The combination of tobramycin and dexamethasone is among the most widely used combinations, however, treatment duration and the need for tapering posology over several weeks may favour the development of bacterial resistance. The study treatment associating a broad-spectrum antibiotic with a highly effective corticosteroid that can be used for a short period of time (one week) is therefore of considerable interest.

The aim of this study is to evaluate the non-inferiority of the study treatment, used for a limited period of time and followed by dexamethasone alone, compared to standard treatment in preventing and treating ocular inflammation and in preventing post-operative infection while limiting the emergence of antibiotic resistance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomized, parallel-group study
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Levofloxacin + Dexamethasone followed by dexamethasone

Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).

Group Type EXPERIMENTAL

Levofloxacin + dexamethasone followed by dexamethasone

Intervention Type DRUG

Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.

Tobramycin + dexamethasone

Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).

Group Type ACTIVE_COMPARATOR

Tobramycin + Dexamethasone

Intervention Type DRUG

Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levofloxacin + dexamethasone followed by dexamethasone

Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.

Intervention Type DRUG

Tobramycin + Dexamethasone

Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Levofloxacin + dexamethasone followed by Maxidex Tobradex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed written informed consent
2. Male or female, age ≥40 years
3. Scheduled senile or presenile cataract surgery
4. Willing to interrupt the use of contact lenses for the entire duration of the study
5. Able and willing to follow study procedures
6. Female patients must be postmenopausal, surgically sterile or must agree to use an effective method of contraception

7. Surgery completed without complications

Exclusion Criteria

1. Ocular conditions that at the discretion of the Investigator may interfere with the efficacy and/or safety evaluations
2. Patients undergoing bilateral cataract surgery
3. Patients under treatment with prostaglandin analogues or intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs
4. Systemic diseases that may interfere with the results of the study
5. Any condition that could interfere with correct instillation of eye drops
6. Ocular surgery in the study eye (including laser surgery) in the 3 months before screening
7. Monocular patients
8. Visual Acuity \< 20/80 of the contralateral eye measured as ETDRS or Snellen
9. Contraindications to ocular treatment with Tobradex®, Maxidex® or levofloxacin/dexamethasone
10. Hypersensitivity to the study product or its excipients
11. Participation in other clinical studies within at least 5 half-lives of the Investigational Medicinal Product (IMP) used in the previous studies
12. Pregnancy or breastfeeding
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NTC srl

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesco Bandello, Prof.

Role: PRINCIPAL_INVESTIGATOR

Ospedale San Raffaele IRCCS S.r.l.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

A.O.U. Osp. Riuniti Umberto I - G.M. Lancisi - G. Salesi - Università degli Studi di Ancona

Ancona, AN, Italy

Site Status

Ospedale della Murgia "Fabio Perinei" di Altamura

Altamura, BA, Italy

Site Status

A.O.U. Policlinico Consorziale di Bari

Bari, BA, Italy

Site Status

ASL Bari - Ospedale "Di Venere" - Carbonara di Bari

Bari, BA, Italy

Site Status

Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni di Bergamo

Bergamo, BG, Italy

Site Status

A.O.U. di Bologna - Policlinico S. Orsola-Malpighi di Bologna

Bologna, BO, Italy

Site Status

Policlinico S. Orsola-Malpighi di Bologna

Bologna, BO, Italy

Site Status

ASST degli Spedali Civili di Brescia - P.O. Spedali Civili di Brescia

Brescia, BS, Italy

Site Status

ASST Franciacorta - P.O. di Chiari

Chiari, BS, Italy

Site Status

P.O. Ospedale Clinicizzato SS. Annunziata di Chieti

Chieti, CH, Italy

Site Status

Ospedale Valduce di Como

Como, CO, Italy

Site Status

A.O.U. Policlinico Vittorio Emanuele - P.O. Gaspare Rodolico - Università degli Studi di Catania

Catania, CT, Italy

Site Status

Policlinico G.B. Morgagni di Catania - Casa di Cura s.r.l.

Catania, CT, Italy

Site Status

A.O. Mater Domini di Catanzaro - Università degli Studi Magna Graecia di Catanzaro

Catanzaro, CZ, Italy

Site Status

IRCCS Casa Sollievo della Sofferenza di San Giovanni Rotondo

San Giovanni Rotondo, FG, Italy

Site Status

A.O.U. Careggi di Firenze

Florence, FI, Italy

Site Status

IRCCS Ospedale Policlinico San Martino di Genova

Genova, GE, Italy

Site Status

Ospedale Policlinico San Martino - Università degli Studi di Genova

Genova, GE, Italy

Site Status

Fatebenefratelli - Ospedale "Sacra Famiglia" di Erba

Erba, LC, Italy

Site Status

Az. USL Toscana Nord Ovest - Ospedale della Versilia

Lido di Camaiore, LU, Italy

Site Status

AUSL Toscana Nord Ovest - P.O. San Luca di Lucca

San Filippo, LU, Italy

Site Status

A.O.U. Policlinico "G. Martino" di Messina

Messina, ME, Italy

Site Status

ASP di Messina - P.O. "Giuseppe Fogliani" di Milazzo

Milazzo, ME, Italy

Site Status

ASST Ovest Milanese - Ospedale Civile di Legnano

Legnano, MI, Italy

Site Status

IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

Milan, MI, Italy

Site Status

Gruppo Multimedica - Ospedale San Giuseppe di Milano

Milan, MI, Italy

Site Status

Ospedale San Raffaele IRCCS S.r.l.

Milan, MI, Italy

Site Status

ASST Fatebenefratelli Sacco - Università degli Studi di Milano - Ospedale L. Sacco

Milan, MI, Italy

Site Status

IRCCS Istituto Clinico Humanitas di Rozzano

Rozzano, MI, Italy

Site Status

ASST di Melegnano e della Martesana - Ospedale di Vizzolo Predabissi

Vizzolo Predabissi, MI, Italy

Site Status

A.O.U. Policlinico di Modena - Università degli Studi di Modena e Reggio Emilia

Modena, MO, Italy

Site Status

Ospedale di Sassuolo

Sassuolo, MO, Italy

Site Status

Centro Polispecialistico Monterosso di Carrara

Carrara, MS, Italy

Site Status

A.O.U. Policlinico "P. Giaccone" di Palermo

Palermo, PA, Italy

Site Status

A.O. "Ospedali Riuniti Villa Sofia-Cervello" di Palermo - P.O. "Villa Sofia" di Palermo

Palermo, PA, Italy

Site Status

AUSL di Piacenza - Ospedale "Guglielmo da Saliceto" di Piacenza

Piacenza, PC, Italy

Site Status

Az. ULSS 6 Euganea - Ospedali Riuniti Padova Sud - Ospedale Madre Teresa di Calcutta-Schiavonia

Monselice, PD), Italy

Site Status

Az. ULSS 6 Euganea - Ospedale S. Antonio - Centro Oculistico San Paolo di Padova

Padua, PD, Italy

Site Status

A.O. di Perugia - Ospedale S. Maria della Misericordia di Perugia

Perugia, PG, Italy

Site Status

Fondazione IRCCS Policlinico S. Matteo - Università degli Studi di Pavia

Pavia, PV, Italy

Site Status

Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli di Reggio Calabria

Reggio Calabria, RC, Italy

Site Status

Policlinico Universitario Campus Bio-medico di Roma

Roma, RM, Italy

Site Status

Fondazione PTV Policlinico Tor Vergata

Roma, RM, Italy

Site Status

A.O.U. Sant'Andrea di Roma

Roma, RM, Italy

Site Status

IRCCS Fondazione G.B. Bietti di Roma

Roma, RM, Italy

Site Status

ASL Roma 4 - Ospedale San Paolo di Civitavecchia

Civitavecchia, RN, Italy

Site Status

Az. ULSS 5 Polesana - Ospedale "Santa Maria della Misericordia"

Rovigo, RO, Italy

Site Status

A.O.U Città della Salute e della Scienza di Torino - Ospedale Molinette

Torino, TO, Italy

Site Status

Az. Sanitaria Universitaria Integrata di Trieste - Ospedali Riuniti di Trieste - Ospedale Maggiore

Trieste, TS, Italy

Site Status

Az. ULSS 2 Marca Trevigiana - Ospedale di Treviso

Treviso, TV, Italy

Site Status

Az. Sanitaria Universitaria Integrata di Udine - P.O. Universitario "Santa Maria della Misericordia" diUdine

Udine, UD, Italy

Site Status

Az. ULSS 7 Pedemontana - Ospedale San Bassiano di Bassano del Grappa

Bassano del Grappa, VI, Italy

Site Status

Ospedale Sacro Cuore - Don Calabria di Negrar

Negrar, VR, Italy

Site Status

A.O.U. Integrata di Verona - Ospedale Borgo Roma

Verona, VR, Italy

Site Status

Az. Osp. di Rilievo Nazionale "A. Cardarelli" di Napoli

Napoli, , Italy

Site Status

A.O.U. "Maggiore della Carità" di Novara

Novara, , Italy

Site Status

A.O.U. Senese - Università degli Studi di Siena

Siena, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LEVODESA_04-2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Bioequivalence Study of Tobradex AF
NCT00362895 COMPLETED PHASE3